Board seat invitations arrive more frequently for senior life sciences executives than for their peers in most other industries, partly because the biotech ecosystem generates a large number of companies that need governance and partly because the scientific and regulatory expertise required to oversee a clinical-stage company is concentrated in a relatively small pool of qualified professionals. The question is rarely whether you will be offered a biotech board seat — it is whether you should accept it, and when.
The answer depends on understanding three things that most professionals underestimate: the actual compensation (which is modest), the legal liability (which is real), and the career implications (which are significant but not always positive). This piece covers the specific dynamics of biotech board service, where the clinical-stage risk profile, the D&O insurance landscape, and the distinction between scientific advisory boards and boards of directors create a decision framework that differs materially from board service in other industries.
Scientific advisory board vs board of directors
The most important distinction in biotech board service is between the scientific advisory board (SAB) and the board of directors — a distinction that many senior professionals blur in their career planning. The two roles differ in every dimension that matters: legal responsibility, time commitment, compensation, and career signaling.
The scientific advisory board is an informal body with no fiduciary duty and no legal liability. SAB members provide scientific and clinical advice to management, review data, and lend their names and reputations to the company’s credibility with investors and regulators. Compensation is typically modest: $2,000 to $5,000 per meeting (with 2-4 meetings per year), plus a small equity grant of 0.01% to 0.05% of fully diluted shares. SAB membership requires 20 to 40 hours per year and carries no D&O liability exposure. For early-career executives and academic physicians building industry relationships, SAB membership is a low-risk entry point that can lead to more substantive board roles.
The board of directors is a legal governing body with fiduciary duties of care and loyalty. Board members can be named individually in shareholder suits, securities class actions, and regulatory investigations. The time commitment is 150 to 300 hours per year, including preparation for quarterly meetings, committee participation, and ongoing engagement with management between meetings. The compensation is meaningfully higher, but so is the risk.
The career signaling difference is also significant: SAB membership signals scientific credibility but does not signal governance capability. Board of directors membership signals both, and is weighted heavily by search committees evaluating CEO and C-suite candidates for future roles. Professionals who accept SAB roles hoping they will "count" as board experience for future governance opportunities are consistently disappointed; the market treats them as fundamentally different credentials.
D&O liability at clinical-stage companies
The directors and officers (D&O) liability profile at clinical-stage biotech companies is materially higher than at comparable-size companies in other industries. Three specific risk factors elevate the exposure:
Securities class action risk. Biotech companies are disproportionately represented in securities class action lawsuits. When a clinical trial fails and the stock drops 50% to 80% in a single session, plaintiff’s attorneys file suit alleging that the company’s directors and officers made misleadingly optimistic statements about the trial’s prospects. In 2023, biotech companies accounted for 22% of all securities class action filings despite representing less than 8% of public company market capitalization. Board members are named individually in these suits, and while D&O insurance typically covers defense costs and settlements, the personal disruption of litigation is substantial.
FDA enforcement risk. Board members at pharmaceutical companies can face personal liability in connection with FDA enforcement actions, particularly in cases involving manufacturing deficiencies, fraudulent clinical data, or off-label promotion. The "responsible corporate officer" doctrine holds that senior corporate officials can be held criminally liable for regulatory violations even without personal knowledge or intent — a legal framework that has been applied to pharmaceutical company directors in several notable cases.
D&O insurance adequacy. Clinical-stage biotech companies typically carry D&O insurance policies with coverage limits of $5M to $20M. For companies with market capitalizations under $200M, these limits may be adequate. For companies that have recently IPO’d at higher valuations, the D&O coverage may not fully protect directors in a major securities class action, where defense costs alone can exceed $5M and settlements can reach $20M to $50M or more. Before accepting a board seat, request the company’s D&O insurance policy summary — specifically the coverage limit, the retention (deductible), and any exclusions that apply to clinical trial-related claims.
Career implications of board service
Board service at a biotech company can meaningfully accelerate a senior career when it provides exposure to governance practices, investor relations, and strategic decision-making contexts that differ from operational executive roles. Several specific career benefits are well-documented in our placement data:
CEO pipeline credentialing. In our tracking of pharma and biotech CEO searches, 68% of successful CEO candidates had at least one corporate board directorship on their resume. Board service provides direct exposure to the governance perspective that CEO candidates are expected to have, and search committees consistently weight board experience as a positive differentiator among otherwise comparable candidates.
Cross-therapeutic-area exposure. A CMO who serves on the board of a gene therapy company while running clinical development at an oncology company gains strategic familiarity with a different modality, different regulatory pathways, and different commercial dynamics. This cross-pollination is valuable for professionals building toward broader executive roles (CEO, CSO at a platform company) where multi-modality experience is a competitive advantage.
Network expansion. Board service introduces you to the company’s investors, advisors, and partner companies in a context of shared governance responsibility. These relationships are qualitatively different from — and often deeper than — relationships built through industry conferences or professional associations. Several executives in our network trace their subsequent CEO appointments directly to relationships built during prior board service.
The career risks of board service are less often discussed but equally real. Reputational association with a failed company can affect your standing in the market, even if the failure was unrelated to your governance contributions. Time commitment during a crisis can impair your performance in your primary operating role, creating a conflict that is difficult to manage gracefully. And conflicts of interest between your board role and your operating role — particularly if the two companies compete in the same therapeutic area — can create both legal exposure and professional awkwardness.
When to accept a biotech board seat
Based on our experience advising senior life sciences executives on board opportunities, the strongest candidates for board service share several characteristics:
Your operating role is stable and well-delegated. If you are currently in the first 18 months of a new C-suite position, or if your company is in the midst of a pivotal clinical trial that requires your full attention, accepting a board seat creates an attention-splitting risk that experienced boards can detect. The ideal timing is 2 to 4 years into a stable operating role, when your team is performing well and your personal bandwidth has genuine capacity for governance work.
The company’s therapeutic area or modality complements your operating experience. Board service in a closely adjacent — but not directly competing — therapeutic area provides the maximum career development benefit with the minimum conflict-of-interest risk. A VP of Clinical Development in oncology serving on the board of an oncology diagnostics company, or a CMO in rare disease serving on the board of a gene therapy platform company, are examples of complementary alignment.
The D&O insurance and indemnification package is adequate. This is a threshold requirement, not a nice-to-have. If the company’s D&O coverage is less than $10M, or if the policy contains broad exclusions for clinical trial-related claims, the personal risk may not be worth the compensation. Negotiate for a separate indemnification agreement with the company, in addition to the D&O policy, that provides personal coverage beyond the policy limits.
Compensation is fair for the risk. At clinical-stage biotech companies, board compensation in our 2024-2025 data ranges from $45,000 to $65,000 in annual cash retainer, plus equity grants of 0.1% to 0.3% of fully diluted shares vesting over 3 to 4 years. Committee chairs receive an additional $10,000 to $20,000 annually. Audit committee membership, given the elevated liability, should command the highest committee premium. If the compensation offered is below these ranges, negotiate — the company is asking you to accept real risk and real time commitment, and under-compensation is a signal that the board may not fully value independent director contributions.
When to decline
Decline when any of the following conditions exist:
- The company has known governance, financial, or regulatory problems that you would be inheriting as a board member. Joining the board of a company under SEC investigation or with an FDA warning letter is accepting liability for problems you didn’t create.
- The board culture is deferential to management. A board that rubber-stamps management decisions without rigorous review is a board that is not performing its governance function — and one that is more likely to face legal liability when things go wrong. Ask to observe a board meeting or speak with existing independent directors before accepting.
- Your operating role would create a conflict of interest. If your current company competes with the board company in the same therapeutic area, the conflict risk outweighs the career benefit. Even if both companies’ general counsels approve the arrangement, the practical reality of managing information barriers between competing companies is more burdensome than most professionals anticipate.
- The time commitment is uncertain. A clinical-stage company approaching a pivotal readout or an M&A process can demand 500+ hours of board time in a single year. If the company’s near-term trajectory includes events that could dramatically increase time requirements, assess whether your operating role can absorb the impact.
Final thoughts
Biotech board service is a consequential career decision that should be evaluated with the same rigor you would apply to a new operating role. The compensation is real but modest relative to the time and risk. The career benefits are genuine but contingent on selecting the right company, the right timing, and the right governance context. And the legal exposure, particularly at clinical-stage companies where securities litigation risk is elevated, requires diligence that goes beyond reviewing the offer letter.
For senior life sciences professionals evaluating their first biotech board seat, the path often starts with SAB membership at 1-2 companies to build governance familiarity, followed by a private company board seat to establish the credential, and eventually a public company directorship where the compensation, network access, and career signaling value are highest. The key is patience: rushing into the wrong board seat is worse than waiting for the right one. For related context on the leadership dynamics shaping biotech governance, see our C-suite turnover analysis and our CMO role and compensation guide.